Short answer
Charles River Laboratories (CRL) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania.
Charles River Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Acquisition agreement for Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania
- Expands Charles River’s drug-development services footprint through added bioanalysis and DMPK capabilities
- Transaction terms and expected financial impact require review of Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Acquisition price approximately $470 million cash, plus up to $75 million performance-based payments
- Target includes Frontage’s Exton, Pennsylvania bioanalysis and DMPK operations, two sites, approximately 340 employees
- Acquired businesses represented approximately 40% of Frontage’s 2025 revenue of $256.7 million
- Closing targeted for first half of 2027, subject to shareholder, regulatory and court approvals
- Financing through Charles River’s credit facility and available cash, with non-GAAP EPS neutral in 2027 and accretive thereafter
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Charles River Laboratories 8-K filings
Get the next CRL 8-K as it lands
Follow CRL for push alerts, or ask the research agent what this filing means.